Healthcare Industry News: sanofi-aventis
News Release - March 10, 2008
OREXIGEN(TM) Therapeutics Appoints Carol Baum as Vice President of CommercializationSAN DIEGO--(HSMN NewsFeed)--Orexigen™ Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that Carol Baum assumed the position of Vice President of Commercialization effective today. Ms. Baum brings to Orexigen over twelve years of experience in pharmaceutical product marketing and strategic planning. She replaces Jim Lancaster who has served as the Company’s Vice President of Commercialization since August 2006. Mr. Lancaster resigned from Orexigen effective today to spend more time with his family; however, he plans to continue to serve as a consultant to the Company.
“We are extremely fortunate to bring on a dynamic and multi-talented individual in Carol Baum. She has the ideal skill set to optimize our success in the marketplace while keeping the patient front of mind,” said Gary Tollefson, M.D., Ph.D., President and CEO of Orexigen. “As we approach a ramp-up in the on-site time necessary to support our commercialization efforts, home and family took priority for Jim. We understand and wish him the best. Mr. Lancaster has made significant contributions to Orexigen in the pre-market support of both Contrave™ and Empatic™, and we will continue to look to him as a consultant for support in commercializing our products.”
Prior to joining Orexigen, Ms. Baum held the position of Vice President of Marketing at Neurocrine Biosciences where she developed the strategic and tactical plan to support the U.S. launch of the company’s product candidate. Before Neurocrine, Ms. Baum was a Marketing Director for Aventis Pharmaceuticals (now a part of sanofi-aventis). Earlier in her career, Ms. Baum held planning and product managing positions of increasing responsibility at Washington University School of Medicine, G.D. Searle and Fujisawa Healthcare. Ms. Baum holds a BS from the University of Colorado and an MBA from Webster University.
About Orexigen Therapeutics
Orexigen™ Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave™, which is in Phase III clinical trials, and Empatic™, which is in the later stages of Phase II clinical development.
Source: Orexigen Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.